May 23, 2024 – Page 13 – Goldea Capital

Aurora Mobile to Report First Quarter 2024 Financial Results on June 6, 2024

Written by Customer Service on May 23, 2024. Posted in Public Companies.

SHENZHEN, China, May 23, 2024 (GLOBE NEWSWIRE) — Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services in China, today announced that it will release its unaudited financial results for the first quarter ended March 31, 2024 before the open of U.S. markets on Thursday, June 6, 2024. Aurora Mobile’s management will host an earnings conference call on Thursday, June 6, 2024 at 7:30 a.m. U.S. Eastern Time (7:30 p.m. Beijing time on the same day). All participants must register in advance to join the conference using the link provided below. Please dial in 15 minutes before the call is scheduled to begin. Conference access information will be provided upon registration. Participant Online Registration: https://register.vevent.com/register/BI6b9a5e81258648acbe3cdaf41598ad70 A...

The Board and management of the Company, as well as companies affiliated with them, intend to exercise warrants corresponding to approximately 27 percent of the outstanding warrants of series TO7 in Terranet AB

Written by Customer Service on May 23, 2024. Posted in Public Companies.

Terranet AB (publ) (”Terranet” or the “Company”) hereby announces the Board and management of the Company, as well as companies affiliated with them, intend to exercise their warrants of series TO7, an investment of approximately SEK 3.6 million, corresponding to approximately 27 percent of the total amount of outstanding warrants of series TO7. The subscription period for the warrants of series TO7 is currently ongoing and will continue up until June 3, 2024. The Board and management of the Company, as well as companies affiliated with them, intend to exercise their warrants of series TO7 as detailed below: Name Position Subscribed amount, number of TO7 Subscribed amount, SEK Maida Vale Capital AB Major shareholder 47,358,858 3,457,197 Magnus Andersson CEO 833,331 60,833 Anders Blom Member of the Board 520,000 37,960 Torgny...

Eviden wins 2nd place in the world’s largest cyber defense exercise

Written by Customer Service on May 23, 2024. Posted in Public Companies.

Press Release Eviden wins 2nd place in the world’s largest cyber defense exercise Eviden Poland team, part of the international Poland-Finland team, is on podium for second year in a row Paris, May 23, 2024 – Eviden, the Atos Group business leading in digital, cloud, big data and security today announces that four of its cybersecurity experts based in Poland and two in Romania have participated in the largest international cyber defense exercise, “Locked Shields 2024”, organized by the NATO Cooperative Cyber Defense Center of Excellence (CCDCOE) . Due to the company’s capabilities and the expertise of its people, Eviden representatives from Poland contributed to the Poland-Finland team that was awarded 2nd place, following on from Poland’s 3rd place ranking last year. This year also marks the 2nd...

Share Buyback Transaction Details May 16 – May 22, 2024

Written by Customer Service on May 23, 2024. Posted in Public Companies.

PRESS RELEASE Share Buyback Transaction Details May 16 – May 22, 2024 Alphen aan den Rijn – May 23, 2024 – Wolters Kluwer (Euronext: WKL), a global leader in professional information, software solutions, and services, today reports that it has repurchased 142,727 of its own ordinary shares in the period from May 16, 2024, up to and including May 22, 2024, for €20.9 million and at an average share price of €146.74. These repurchases are part of the share buyback program announced on February 21, 2024, under which we intend to repurchase shares for €1 billion during 2024. The cumulative amounts repurchased in the year to date under this program are as follows: Share Buyback 2024 Period Cumulative shares repurchased in period Total consideration(€ million) Average share price(€) 2024 to date 2,911,319 414.6 142.43 For...

Disclosure of voting rights for Chair of the Board

Written by Customer Service on May 23, 2024. Posted in Public Companies.

Oslo, 23 May 2024. PCI Biotech Holding ASA (“PCI Biotech” or the “Company”) issue this notification on behalf of Hans Peter Bøhn, Chair of the Board of Directors. Hans Peter Bøhn is chair of PCI Biotech’s board of directors and shall open the annual general meeting of the Company on 24 May 2024. Mr. Bøhn holds 123,662 shares, representing 0.3 percent of the share capital of PCI Biotech. Mr. Bøhn has received powers of attorney to represent and vote for 4,288,185 additional shares. In total, Mr. Bøhn will represent and vote for 11.8 percent of the share capital. A major part of the powers of attorney are without voting instructions. The powers of attorney are only valid at the annual general meeting on 24 May 2024. This information is subject to the disclosure requirements pursuant to section 4 -3, cf. section 5-12...

ONWARD® Medical Reports Q1 2024 Update and Year-to-Date Highlights

Written by Customer Service on May 23, 2024. Posted in Public Companies.

Nature Medicine published Up-LIFT pivotal trial results Submitted FDA De Novo application for ARC-EX® System Successfully raised EUR 20M in equity capital EINDHOVEN, the Netherlands, May 23, 2024 (GLOBE NEWSWIRE) — ONWARD Medical N.V. (Euronext: ONWD), a medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today provided a Q1 2024 business update. “This week’s publication of Up-LIFT pivotal trial results in Nature Medicine underscores the tremendous potential of ARC-EX Therapy to restore independence in daily activities for people with spinal cord injury,” said Dave Marver, CEO of ONWARD Medical. “We are working closely with the FDA toward clearance for the ARC-EX System and we are preparing to introduce this technology...

Fingerprints announces final terms for the partially guaranteed rights issue

Written by Customer Service on May 23, 2024. Posted in Public Companies.

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE. On 26 April 2024, the Board of Directors of Fingerprint Cards AB (publ) (“Fingerprints” or the “Company”) announced that the Board of Directors resolved to, subject to subsequent approval by the annual general meeting on 28 May 2024, carry out a partially guaranteed issue of new shares of series B (“B-shares”) of up to approximately SEK 310 million with preferential rights for its existing shareholders (the “Rights Issue”). Today, Fingerprints’...

Ackermans & van Haaren reports outstanding Q1-results at both DEME and at the private banks Delen and Van Breda, and gives confirmation of guidance: net profit of 2024 expected to be higher than last year

Written by Customer Service on May 23, 2024. Posted in Earnings Releases And Operating Results.

Dear shareholder, Dear Madam, Dear Sir, Ackermans & van Haaren has published today its Trading Update on the 1st quarter of 2024, with the following key items: Outstanding Q1-results at both DEME and at the private banks Delen and Van Breda Confirmation of guidance: net profit of 2024 expected to be higher than last year Please find in annex the full press release Best regards Ackermans & van Haaren Attachment AvH press release – 1Q2024 Trading Update

Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease

Written by Customer Service on May 23, 2024. Posted in Earnings Releases And Operating Results.

Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease Additional kidney function analyses strongly support Vivoryon’s shift in strategic focus to inflammatory and fibrotic diseases, and are a further step towards securing Company’s future Varoglutamstat`s beneficial effect of improving kidney function, as demonstrated by an increase of estimated glomerular filtration rate (eGFR), confirmed by various sensitivity and subgroup analyses A significant and dose dependent reduction of the pyroglutamated version of CCL2 (pE-CCL2) in serum demonstrates effectiveness of varoglutamstat in inhibiting systemic intracellular QPCT/L and strongly supports an anti-inflammatory effect Alzheimer’s disease: No consistent effect on cognition could be shown in a subgroup of VIVIAD participants...

IBA Business Update – First Quarter 2024

Written by Customer Service on May 23, 2024. Posted in Earnings Releases And Operating Results.

Louvain-la-Neuve, Belgium, 23 May 2024 – IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its business update for the first quarter ending 31 March 2024. Group Overview Good Group order intake at end of March, driven by continued growth in Other Accelerators, with typical strong second half weighting expected Group backlog remains at a high of EUR 1.4 billion EUR 30.1 million net cash position, decreasing as a result of a planned procurement of inventory, related to backlog conversion and among others the ten-room Proteus®ONE1 contract in Spain B Corp certification renewed with a significantly improved score of 114 points (2021: 90 points), placing the Group among the top 10% of those certified globally Olivier Legrain, Chief Executive Officer of IBA commented: “IBA has had...

Day: May 23, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice